Hemorrhagic Cystitis Following Allogeneic Hematopoietic Cell Transplantation.
10.3346/jkms.2003.18.2.191
- Author:
Gyeong Won LEE
1
;
Je Hwan LEE
;
Seong Jun CHOI
;
Shin KIM
;
Miee SEOL
;
Woo Kun KIM
;
Jung Shin LEE
;
Kyoo Hyung LEE
Author Information
1. Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. jhlee3@www.amc.seoul.kr
- Publication Type:Original Article
- Keywords:
Cytomegalovirus Cystitis;
Hematopoietic Stem Cell Transplantation;
Graft vs Host Disease
- MeSH:
Adult;
Cystitis/epidemiology;
Cystitis/etiology*;
Cystitis/pathology;
Female;
Graft vs Host Disease/complications;
Graft vs Host Disease/pathology;
Hematopoietic Stem Cells/physiology*;
Hemorrhagic Disorders/epidemiology;
Hemorrhagic Disorders/etiology*;
Hemorrhagic Disorders/pathology;
Human;
Male;
Multivariate Analysis;
Retrospective Studies;
Risk Factors;
Stem Cell Transplantation/adverse effects*;
Transplantation Conditioning
- From:Journal of Korean Medical Science
2003;18(2):191-195
- CountryRepublic of Korea
- Language:English
-
Abstract:
We conducted a retrospective study to investigate the incidence, risk factors, and clinical features of hemorrhagic cystitis (HC) following allogeneic hematopoietic cell transplantation (allo-HCT). Adult patients who developed HC after allo-HCT were identified from the HCT database of the Asan Medical Center and their medical records were reviewed. From December 1993 to August 2001, a total of 210 adult patients underwent allo-HCT. Fifty-one patients developed HC with a cumulative incidence of 25.7%. The median onset of HC was post-transplant day 24 (range, -2 to 474), and the median duration was 31 days (range, 8 to 369). Significant risk factors for HC by univariate analysis included diagnosis of chronic myelogenous leukemia (p=0.028), unrelated HCT (p=0.029), grade III-IV acute graft-versus-host disease (GVHD) (p<0.001), extensive chronic GVHD (p=0.001), and positive cytomegalovirus antigenemia between post transplant days 31 and 60 (p=0.031). Multivariate analysis showed that grade III-IV acute GVHD was the most important risk factor for the occurrence of HC after allo-HCT (odds ratio, 3.38; 95% CI, 1.36-8.39). Late-onset HC, which occurred beyond 3 weeks after allo-HCT, was more frequently associated with GVHD than earlyonset HC (p=0.007). Our data suggest that a portion of late-onset HC might be a manifestation of GVHD.
